AgingResearch.NewsJoin free

Heart failure exacerbation

Disease

3 papers2 findings

  • Humans2

Associations

2

Tirzepatide

downin humans1OR 1.24

1 study

  1. Tirzepatide lowers the risk of heart failure exacerbation in humans (OR 1.24, p=0.012).

    “heart failure exacerbations were more frequent with Semaglutide (10.1% vs 8.3%; OR 1.24, p=0.012).”

    Humansin adults with HFpEF and obesityn = 40,047

    Comparative Cardiometabolic Outcomes of Tirzepatide Versus Semaglutide in Patients with HFpEF and Obesity: A Real-World Multicenter Cohort Study

    AHA Scientific Sessions 2025 abstractNov 3, 2025

More on Tirzepatide

GLP-1 receptor agonists

downin humans1RR 0.22

1 study

  1. GLP-1 receptor agonists lower the risk of heart failure exacerbation in humans (0.8% vs 3.7%, RR 0.220).

    “HF-exa (0.8% vs 3.7%; RR 0.220; p<0.001)”

    Humansdilated cardiomyopathy without diabetes1 year

    Use Of Glucagon Like Peptide 1 Receptor Agonists In Non Diabetic Patients With Dilated Cardiomyopathy

    AHA Scientific Sessions 2025 abstractNov 3, 2025

More on GLP-1 receptor agonists

Latest

Nov 2025: 9Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 2Oct 2026: 011 in 12 months
The Journal of Nutrition, Health & Aging

Intrinsic capacity outperforms frailty in cardiac rehab outcomes

In 551 older patients, intrinsic capacity showed a stronger link to post-rehabilitation walking outcomes (β = 0.571) than the frailty index (β = -0.281).In 551 older patients, intrinsic capacity showed a stronger link to post-rehabilitation walking outcomes (β = 0.571) than the frailty index (β = -0.281).

Cohort study of 551 peopleIntrinsic capacity
Paper

Related